Lv4
770 积分 2023-07-23 加入
Clinical-genomic profiling of MDS to inform allo-HSCT:Recommendations from an international panel on behalf of the EBMT
17小时前
待确认
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post‐transplant cyclophosphamide versus conventional anti‐graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
1个月前
已完结
Does IPSS-R down staging before transplantation improve the prognosis of patients with Myelodysplastic neoplasms?
1个月前
已关闭
Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants
1个月前
已完结
How I reduce and treat posttransplant relapse of MDS
1个月前
已关闭
Effect of donor type in patients with AML or MDS undergoing reduced intensity hematopoietic cell transplant
1个月前
已关闭
Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
1个月前
已完结
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)
1个月前
已关闭
Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT
1个月前
已完结
[Comparison of three different types of donor hematopoietic stem cell transplantation for intermediate and high-risk myelodysplastic syndrome]
1个月前
已关闭
皖公网安备34019202002308
